Lupus News and Research

Latest Lupus News and Research

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

28 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Children born to mothers with lupus have twice the risk of autism spectrum disorders

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

28 Oct 2013

Study shows low uptake of HPV vaccination among patients with autoimmune diseases

The number of children and young adults with autoimmune diseases receiving the HPV vaccination is profoundly low despite studies showing the vaccine to be safe and effective, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. Given the increased incidence of HPV in people with autoimmune diseases, this research suggests that increased public health efforts are needed.

28 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Lupus disparities: Young, black women have highest rate of developing lupus

Young, black women have the highest rate of developing lupus and are most likely to be diagnosed at a younger age than whites and during childbearing years, according to a new University of Michigan study of lupus in Southeastern Michigan.

25 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

A National autoimmune disease multi-city conference tour arrives in Charleston, SC on Saturday, November 2, 2013. The conference "What Every American Needs to Know About Autoimmune Disease," is one of a series of free patient forums hosted by the American Autoimmune Related Diseases Association.

15 Oct 2013

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

With the completion of the first genome-wide association study for Sj-gren's syndrome, an international coalition of researchers led by scientists at the Oklahoma Medical Research Foundation has identified six new disease-related genes.

7 Oct 2013

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

c-Fos oncogene cab be important target for understanding and treatment of cancer

The c-Fos oncogene has traditionally been linked to cellular activities related to cancer, such as cell division, differentiation-conversion from one cell type to another-or survival. Any alteration of these activities can set off the development of tumours, which has made c-Fos an important target for the understanding and treatment of cancer.

29 Sep 2013

Study shows need for improved detection of sepsis for all women in labor

Rates of severe sepsis and deaths from sepsis among U.S. women hospitalized for delivery have risen sharply over the last decade, reports a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Sep 2013

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

...

23 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

Antibody that binds, neutralizes HIV likely also targets the body's own self proteins

Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.

20 Sep 2013

Parasites could be potential key to treating autoimmune diseases

There is a new weapon in the fight against autoimmune diseases such as Type 1 diabetes, rheumatoid arthritis, Crohn's disease and lupus, the common trait of which is an immune system that attacks its own organs and tissues.

10 Sep 2013

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

...

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Lupus News and Research

Latest Lupus News and Research

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

DPP-4 inhibitors may reduce risk of autoimmune diseases

Children born to mothers with lupus have twice the risk of autism spectrum disorders

Study shows low uptake of HPV vaccination among patients with autoimmune diseases

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Lupus disparities: Young, black women have highest rate of developing lupus

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

c-Fos oncogene cab be important target for understanding and treatment of cancer

Study shows need for improved detection of sepsis for all women in labor

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Antibody that binds, neutralizes HIV likely also targets the body's own self proteins

Parasites could be potential key to treating autoimmune diseases

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Lupus News and Research

Latest Lupus News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in